S.C. Ropharma Reports Full Year 2024 Earnings

Simply Wall St

May 10, 2025

S.C. Ropharma (BVB:RPH) Full Year 2024 Results

Key Financial Results

Revenue: RON1.33b (up 19% from FY 2023).
Net loss: RON1.73m (down by 122% from RON7.72m profit in FY 2023).

We've discovered 3 warning signs about S.C. Ropharma. View them for free.

earnings-and-revenue-history — BVB:RPH Earnings and Revenue History May 10th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

S.C. Ropharma shares are down 5.7% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 3 warning signs for S.C. Ropharma (2 are significant) you should be aware of.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.